散血明目片联合康柏西普对PCV并发玻璃体积血患者术后的影响  

Effect of Sanxue Mingmu Tablet(散血明目片)Combined with Conbercept on Postoperative Patients with Polypoid Choroidal Vasculopathy Complicated with Vitreous Hemorrhag

作　　者：黄学思[1] 彭俊[2] 曾志成 沈志华[4] 蒋鹏飞[5] 陈向东[2] 彭清华[5] HUANG Xuesi;PENG Jun;ZENG Zhicheng;SHEN Zhihua;JIANG Pengfei;CHEN Xiangdong;PENG Qinghua(The First Affiliated Hospital of Hunan College of Traditional Chinese Medicine,Zhuzhou 412008,China;The First Hospital of Hunan University of Chinese Medicine,Changsha 410007,China;The First People’s Hospital of Guiyang County,Chenzhou 424400,China;Shenzhen Eye Hospital,Shenzhen 518040,China;Hunan University of Chinese Medicine,Changsha 410208,China)

机构地区：[1]湖南中医药高等专科学校附属第一医院,湖南株洲412008 [2]湖南中医药大学第一附属医院,湖南长沙410007 [3]湖南省桂阳县第一人民医院,湖南郴州424400 [4]广东省深圳市眼科医院,广东深圳518040 [5]湖南中医药大学,湖南长沙410208

出　　处：《山东中医杂志》2021年第8期812-816,共5页Shandong Journal of Traditional Chinese Medicine

基　　金：湖南省重点实验室建设项目(编号:2017TP1018);国家中医药管理局中医眼科学重点学科建设项目(编号:ZK1801YK015);湖南中医药大学中医学国内一流建设学科建设项目(编号:2018-2020);湖南省工程技术研究中心建设项目(编号:2018TP2008)。

摘　　要：目的:观察散血明目片对息肉状脉络膜血管病变(PCV)并发玻璃体积血(VH)患者术后血流动力学等相关指标的影响。方法:将76例PCV并发VH的患者按随机数字表法分为对照组和观察组,每组38例。对照组行玻璃体切除治疗,术后1个月行玻璃体腔注射康柏西普治疗,观察组在对照组的基础上于玻璃体腔注射康柏西普后1 d加用散血明目片口服治疗。治疗前1 d及治疗1个月、2个月、3个月、6个月后,观察两组患者最佳矫正视力(BCVA),超声检测两组患者眼部睫状后短动脉收缩期峰值流速(PSV)、舒张末期流速(EDV)及阻力指数(RI),光学相干断层成像检测两组患者黄斑中心凹厚度(CMT)。结果:治疗后两组各时段BCVA均优于治疗前(P<0.05),治疗后2个月、3个月、6个月观察组BCVA优于对照组(P<0.05);治疗后两组PSV、EDV、RI均有所改善(P<0.05),治疗后2个月、3个月、6个月观察组PSV、EDV高于对照组(P<0.05),治疗后3个月、6个月观察组RI低于对照组(P<0.05);治疗后两组各时段CMT均低于治疗前(P<0.05),治疗后2个月、3个月、6个月观察组CMT低于对照组(P<0.05)。结论:散血明目片联合康柏西普治疗较单纯康柏西普治疗能更好地减轻视网膜水肿,提高视力、降低CMT与RI,对PSV、EDV有更好的改善作用。Objective:To observe the effect of Sanxue Mingmu Tablet(散血明目片)on postoperative hemorheology in patients with polypoid choroidal vasculopathy(PCV)complicated with vitreous hemorrhage(VH).Methods:Seventy-six patients with PCV complicated with VH were randomly divided into observation group and control group using a random table,38 patients in each group.The control group was given vitrectomy,and 1 month after the operation,patients were given intravitreal injection of conbercept.In the observation group,besides the treatment in the control group,patients were also given oral administration of Sanxue Mingmu Tablet 1 day after the intravitreal injection.One day before the treatment,and one month,two months and six months after the treatment,the best corrected visual acuity(BCVA)was observed,the peak systolic velocity(PSV),end diastolic velocity(EDV),and resistance index(RI)of the short posterior ciliary artery(SPCA)were examined with a ultrasonic detector,and the central macular thickness(CMT)was detected with optical coherence tomography.Results:BCVA in both groups was improved after the treatment(P<0.05),and 2 months,3 months and 6 months after the treatment,BCVA in the observation group was better than that in the control group(P<0.05);PSV and EDV in both groups were higher after the treatment(P<0.05),and 2 months,3 months,and 6 months after the treatment,PSV and EDV in the observation group were higher than that in the control group(P<0.05);RI in both groups was decreased after the treatment(P<0.05),and 3 months,6 months after the treatment,RI in the observation group was lower than that in the control group(P<0.05);CMT in both groups was decreased after the treatment(P<0.05),and 2 months,3 months and 6 months after the treatment,CMT in the observation group was lower than that in the control group(P<0.05).Conclusion:Conbercept combined with Sanxue Mingmu Tablet is better than compercept alone on reducing retinal edema,improving vision,reducing CMT and RI,and improving the PSV and EDV.

关 键 词：散血明目片 活血利水 息肉状脉络膜血管病变 玻璃体积血 康柏西普 血流动力学 

分 类 号：R276.7[医药卫生—中医五官科学]